1985

Spiro Rombotis, president and CEO of Cyclacel Pharmaceuticals Inc., and his colleagues attended the Nasdaq Closing Bell ceremony on May 8. Cyclacel has two cancer drugs on the market and three in clinical trials, with the most advanced in late-stage trials for acute myeloid leukemia in elderly patients.